 |
 |
|---|---|
|
Speaker:
David Wu, MD, PhD |
Moderator:
Lauren Ritterhouse, MD, PhD |
This webinar is a recorded presentation of a live broadcast and includes the presentation, handout, and audience Q&A
CME/CMLE Credit is not available for this webinar.
Description:
This webinar will provide an introductory overview of measuring residual disease in myeloid neoplasms, with a focus on acute myeloid leukemia. This talk will summarize the clinical need, laboratory approaches, and future opportunities and challenges for this testing.
Learning Objectives:
- Review clinical need and opportunities for detecting measurable residual disease (MRD) in myeloid neoplasms, with focus on acute myeloid leukemia
- Discuss challenges with detecting MRD
- Describe technical approaches for detecting MRD in the clinical laboratory
- Review recent literature and progress in this field
This webinar is part 6 of the Emerging and Evolving Biomarkers Series.
This program has been supported through educational grant funding provided by Amgen and Loxo Oncology at Lilly (for further information concerning Lilly grant funding visit www.lillygrantoffice.com.) Supporting companies had no control over its content. No personally-identifiable information regarding you is provided to any grant supporters.
.jpg){kind=small}
AMP is pleased to collaborate in the Immunotherapy Collaborative of Oncology Networked Communities, IC-ONC. IC-ONC is a global information network in which multidisciplinary healthcare providers, responsible for treating patients with cancer, are connected via education.
Please be sure to visit www.ic-onc.org to learn more about the collaborative and all it has to offer.
Note: Join the AMP Family for discounted access to the most current educational resources!
All sales are final. No refunds will be issued.
No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentation
